Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion

• US 20070098697A1
• Filed: 08/31/2006
• Published: 05/03/2007
• Est. Priority Date: 06/02/2000
• Status: Active Grant

• Current Assignee: Terumo BCT Biotechnologies, LLC (Terumo Corporation)
• Original Assignee: Navigant Biotechnologies, Inc. (Baxter International Inc.)
• Inventors: Li, Junzhi, Goodrich, Raymond
• Granted Patent: US 7,648,699 B2
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A01N 1/0215 Disinfecting agents, e.g. antimicrobials for preserving living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61K 35/19 Platelets; Megacaryocytes
• CPC Class Codes: A61K 41/0023 Agression treatment or altering

Abstract

This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion related complication by the recipient to cells in the donor blood. The invention is also directed towards a process for preventing rejection of a donor organ by a recipient comprising the steps of transfusing the recipient of the donor organ with treated platelets; and transplanting the donor organ into the recipient.

Claims

1. A process for reducing transfusion related complications in a recipient due to donor cells that may be present in an allogeneic blood transfusion comprising the steps of:

adding to the blood to be transfused a photosensitizer comprising riboflavin;

irradiating the blood and riboflavin with light for a sufficient period of time to reduce transfusion related complications in the recipient caused by the donor cells;

transfusing the irradiated blood into a recipient; and

reducing transfusion related complications in the recipient.

2. The process of claim 1 wherein the step of reducing transfusion related complications further comprises reducing alloimmunization.

3. The process of claim 1 wherein the step of reducing transfusion related complications further comprises reducing TA-GVHD.

4. The process of claim 1 wherein the step of reducing transfusion related complications further comprises reducing microchimerism.

5. The process of claim 1 wherein the irradiating step further comprises irradiating with light at a wavelength between 290-370 nm.

6. The process of claim 1 wherein the adding step further comprises adding riboflavin to the blood at a concentration of 50 μ

M.

7. The process of claim 1 wherein the irradiating step further comprises irradiating the blood and riboflavin for around 8 minutes.

8. The process of claim 1 wherein the blood to be transfused further comprises whole blood.

9. The process of claim 1 wherein the blood to be transfused further comprises platelets.

10. The process of claim 1 wherein the donor cells causing transfusion related complications further comprise white blood cells.

11. The process of claim 1 wherein the donor cells causing transfusion related complications further comprise platelets.

12. The process of claim 2 wherein the step of reducing alloimmunization further comprises reducing activation of the donor cells in the recipient.

13. The process of claim 2 wherein the step of reducing alloimmunization further comprises reducing proliferation of the donor cells in the recipient.

14. The process of claim 2 wherein the step of reducing alloimmunization further comprises reducing production of cytokines by the donor cells in the recipient.

15. The process of claim 4 wherein the step of reducing microchimerism further comprises reducing production of antibodies by the donor cells in the recipient.

16. A blood product for transfusion into a recipient comprising:

blood or a blood product which has been treated with riboflavin and light

wherein the treated blood or blood product will not cause transfusion related complications in the recipient when transfused.

17. The blood product of claim 16 further comprising platelets.

18. The blood product of claim 16 further comprising whole blood.

19. A process for preventing rejection of a donor organ by a recipient comprising the steps of:

transfusing the recipient of the donor organ with treated platelets; and

transplanting the donor organ into the recipient.

20. The process of claim 19 wherein the treated platelets further comprise platelets treated with riboflavin and light.

21. The process of claim 19 wherein the step of transfusing the recipient further comprises transfusing the recipient with treated platelets for a period of time before the organ transplant.

22. The process of claim 19 wherein the step of transfusing the recipient further comprises transfusing the recipient with treated platelets multiple times before the organ transplant.

23. The process of claim 19 wherein the donor organ to be transplanted into the recipient is allogeneic.

24. The process of claim 19 wherein the donor organ to be transplanted into the recipient is xenogeneic.

25. The process of claim 19 wherein the treated platelets are from an allogeneic donor.

26. The process of claim 19 wherein the treated platelets prevent the development of antibodies to the transplanted organ in the transplant recipient.